1. Scrip
  2. >>Business

AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval

Long Wait For First Tremelimumab Approval Could Soon Be Over

 
• By Andrew McConaghie

AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.

Astrazeneca
AstraZeneca could gain its first approval for the immunotherapy combination by the end of 2022 - but rivals Roche have a head start in liver cancer. • Source: Alamy

After years of struggling to get a positive readout for its cancer immunotherapy candidate tremelimumab, AstraZeneca is in a hurry to get it approved and on the market, and could achieve that goal before the end of 2022 thanks to the use of a priority review voucher.

A biologics license application for tremelimumab has been accepted for priority review by the US Food and Drug Administration for its use as a single priming dose when added to the PDL-L1 inhibitor Imfinzi

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 
• By Alaric DeArment

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

More from Scrip

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Stock Watch: Bayer, Bavarian Nordic Bring European Cheer To Pharma

 
• By Andy Smith

Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.